hiv/aids adverse drug reaction: indinavir decreases nitric oxide production in hiv/aids patients

AIDS Weekly Plus HIV/AIDS Adverse Drug Reaction: Indinavir decreases nitric oxide production in HIV/AIDS patients Staff Medical Writers
October 30, 2006

-- Indinavir decreases nitric oxide production in HIV/AIDS patients. According to a recently published report from Brazil, "Treatment with indinavir (IDV), a protease inhibitor, is frequently associated with renal abnormalities. "We determined the incidence of renal failure (creatinine clearance <80 mL min^-1 1.73 (m²)^-1) in HIV patients treated with highly active antiretroviral therapy, including IDV, and investigated the possible mechanisms and risk factors of IDV nephrotoxicity." "Thirty-six patients receiving IDV were followed for 3 years. All were assessed for age, body weight, duration of infection, duration of IDV treatment, sulfur-derivative use, total cholesterol, triglycerides, magnesium, sodium, potassium, creatinine, and urinalysis. "We also determined renal function in terms of creatinine clearance, urine osmolality and fractional excretion of sodium, potassium, and water. Urinary nitrate (NO₃) excretion was measured in 18 IDV-treated patients and compared with that of 8 patients treated with efavirenz, a drug without renal side effects," investigators wrote. M. Eira and colleagues at the University of Sao Paulo reported, "Sterile leukocyturia occurred in 80.5% of the IDV-treated patients. Creatinine clearance <80 mL min^-1 1.73 (m²)^-1 was observed in 22 patients (61%) and was associated with low body weight and the use of sulfur-derivatives. "These patients also had lower osmolality, lower urine volume and a higher fractional excretion of water compared to the normal renal function group. Urinary NO₃ excretion was significantly lower in IDV-treated patients (809±181 mcM NO₃-/mg creatinine) than in efavirenz-treated patients (2247±648 mcM NO₃-/mg creatinine, p<0.01)." The authors concluded, "The lower NO₃ excretion suggests that IDV decreases nitric oxide production." Eira and colleagues published their study in Brazilian Journal of Medical and Biological Research (Urinary NO₃ excretion and renal failure in indinavir-treated patients. Braz J Med Biol Res. 2006 Aug;39(8):1065-70). For more information, contact M. Eira, Institute Infectol Emilio Ribas, Coordenadoria Service Saude, Secretaria Estado Saude, Av Dr. Arnaldo 165, BR-01246900 Sao Paulo, Brazil. Publisher contact information for the Brazilian Journal of Medical and Biological Research is: Association Bras Divulg Cientifica, Faculdade Medicina, Sala 21, 14049 Ribeirao Preto, Sao Paulo, Brazil. Keywords: Sao Paulo, Brazil, HIV/AIDS, Indinavir, Nephrotoxicity, Renal Failure, Urinary NO3 Secretion. This article was prepared by AIDS Weekly editors from staff and other reports. Reference Eira M, Araujo M, Seguro AC., “Urinary NO3 excretion and renal failure in indinavir-treated patients”, Braz J Med Biol Res. 2006 Aug;39(8):1065-70. PubMED Related articles Search

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 Youth organizations form a pact for social transformation in the AIDS response Kingdom of Bahrain and UNAIDS commit to intensify cooperation CANADA: Celibate Homosexual Men Now Allowed to Donate Blood in Canada AFRICA: UN: AIDS Deaths Down, Treatment Up in Africa MICHIGAN: STD Fee for Jackson County Walk-In Clinic Takes Effect June 3 NEW YORK: Catskill Hospital Warns That Insulin Pens May Have Been Reused DELAWARE: Cape Henlopen Theatre Academy to Host 'Magic to Do' May 25 GLOBAL: HIV Outcomes Could Improve by Integrating Treatment of Comorbid Mental Illness CANADA: Stop Paid Blood Donor Clinics in Toronto, Victims Say UNITED STATES: How Sexual Stigma Is Undermining HIV Treatment on American Indian Reservations Youth organizations form a pact for social transformation in the AIDS response AFRICA: UN: AIDS Deaths Down, Treatment Up in Africa GLOBAL: HIV Outcomes Could Improve by Integrating Treatment of Comorbid Mental Illness UNITED STATES: How Sexual Stigma Is Undermining HIV Treatment on American Indian Reservations HHS Office for Civil Rights launches campaign to increase awareness of HIPAA rights among HIV-positive Black men Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog Living with HIV Global HIV/AIDS leaders meet in SF, Oakland AIDS Walk grants cut Giants, nonprofit mark 20 years of AIDS awareness
Copyright © 2006 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS. Information in this article was accurate in October 30, 2006. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.